Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018

Date: July 17, 2018
Pages: 107
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A7655ACCBB1EN
Leaflet:

Download PDF Leaflet

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 6, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Acute Respiratory Distress Syndrome - Overview
Acute Respiratory Distress Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
Athersys Inc
Bayer AG
Cells for Cells SA
Commence Bio Inc
CompleGen Inc
Cynata Therapeutics Ltd
Faron Pharmaceuticals Oy
GlaxoSmithKline Plc
Hydra Biosciences Inc
Implicit Bioscience Ltd
PaxVax Inc
ProMetic Life Sciences Inc
Savara Inc
SolAeroMed Inc
Windtree Therapeutics Inc
Acute Respiratory Distress Syndrome - Drug Profiles
Aerosurf - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-10901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGX-1037 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HC-067047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multistem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAV-5093 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAV-5188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plasminogen (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXVX-0047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-1229 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
simvastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Respiratory Distress Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TCP-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Respiratory Distress Syndrome - Dormant Projects
Acute Respiratory Distress Syndrome - Discontinued Products
Acute Respiratory Distress Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 14, 2018: Faron Pharmaceuticals: Traumakine biomarker analysis of the Phase III INTEREST trial
May 11, 2018: Faron Pharmaceuticals : Update on the Phase III INTEREST trial of Traumakine in the treatment of ARDS
May 08, 2018: Faron announces top line data from the Phase III INTEREST trial with Traumakine in the treatment of ARDS
Feb 05, 2018: Faron establishes second Traumakine manufacturing site
Jan 29, 2018: FDA grants Fast Track Designation to Faron for Traumakine
Jan 24, 2018: FDA has approved Faron's Traumakine IND
Dec 11, 2017: The patient recruiting of the Traumakinen INTEREST study has ended
Dec 01, 2017: Appointment of Chief Commercial Officer
Oct 02, 2017: Farons Traumakine Receives Promising Innovative Medicine Designation from the MHRA for the Treatment of ARDS
Sep 04, 2017: Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine following completion of European and Japanese Phase III studies
Aug 04, 2017: Faron Pharmaceuticals: IDMC recommends Traumakine Phase III ARDS study to continue as planned
May 08, 2017: Faron Pharmaceuticals: Update on INTEREST Phase III Study for Traumakine in ARDS from IDMC
Apr 25, 2017: Navigen Announces $1.7MM Phase II NIH SBIR Award to Support the Development of ARF6 Inhibitors for Treatment of Acute Lung Injury
Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation
Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Bayer AG, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Cells for Cells SA, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by CompleGen Inc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Cynata Therapeutics Ltd, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by PaxVax Inc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by ProMetic Life Sciences Inc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, H2 2018
Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, H2 2018
Acute Respiratory Distress Syndrome - Dormant Projects, H2 2018
Acute Respiratory Distress Syndrome - Dormant Projects, H2 2018 (Contd.1), H2 2018
Acute Respiratory Distress Syndrome - Discontinued Products, H2 2018

LIST OF FIGURES

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Athersys Inc
Bayer AG
Cells for Cells SA
Commence Bio Inc
CompleGen Inc
Cynata Therapeutics Ltd
Faron Pharmaceuticals Oy
GlaxoSmithKline Plc
Hydra Biosciences Inc
Implicit Bioscience Ltd
PaxVax Inc
ProMetic Life Sciences Inc
Savara Inc
SolAeroMed Inc
Windtree Therapeutics Inc
Skip to top


Ask Your Question

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: